AllSci News
Gilead expands Trodelvy into first-line triple-negative breast cancer with dual FDA approvals
The US FDA approved Trodelvy (sacituzumab govitecan-hziy) for two first-line indications in unresectable locally advanced or metastatic triple-negative breast cancer (TNBC), marking…
Merck KGaA to aquire life sciences tool firm Bio-Techne for USD 11.3b
Germany-based Merck KGaA agreed to acquire Minneapolis-based Bio-Techne Corporation (Nasdaq: TECH) in an all-cash transaction valued at USD 11.3 billion...
Novartis bets USD 1.9b on Antares' covalent chemistry platform for undruggable cancer targets
Novartis has committed up to USD 1.905 billion to access Boston-based Antares Therapeutics' covalent small molecule discovery engine, in one of the largest...
Immunomic's self-amplifying RNA vaccine enters human testing in TNBC
Immunomic Therapeutics Initiates First-in-Human saRNA Cancer Vaccine Trial in Triple-Negative Breast Cancer
BIDMC wins NIH grant to study ADAMTS13 deficiency beyond rare clotting disorder
Beth Israel Deaconess Medical Center (BIDMC) has received a USD 1.63 million NIH R01 grant from the National Heart, Lung, and Blood Institute to investigate...
Brigham and Women's investigates "affinity birth" in B cells to expand antibody repertoire plasticity
Brigham and Women's Hospital has received a USD 3 million NIH R01 grant from the National Institute of Allergy and Infectious Diseases to investigate...
Viking's dual amylin-calcitonin agonist enters clinic to advance combo obesity strategy
San Diego-based Viking Therapeutics (Nasdaq: VKTX) has initiated a Phase I single ascending dose trial of VK3019, an internally developed dual amylin and...
Leyden Labs secures EUR 40m to advance intranasal antibody defense against respiratory viruses
Netherlands-based Leyden Laboratories B.V. (Leyden Labs) announced a €40 million (approximately USD 43.6 million) private placement from a geographically...
Ionis signs ex-US zilganersen licensing deal with Recordati ahead of FDA decision
Ionis locks in a USD 30 million upfront payment and tiered royalties of up to the mid-20% range from Italy-based Recordati (Milan: REC) for exclusive ex-US...
Pfizer expands Ibrance into HER2-positive breast cancer with first CDK4/6 maintenance win
The US FDA approved Ibrance (palbociclib) for a new indication in HR-positive, HER2-positive metastatic breast cancer, marking Pfizer’s first regulatory success for…
FDA approves Ionis’ Tryngolza to cut acute pancreatitis risk in hypertriglyceridemia
The US FDA has approved Tryngolza (olezarsen) — making it the first therapy demonstrated to reduce the risk of acute pancreatitis in…
CeleCor seeking approval for zalunfiban as first antiplatelet therapy for pre-hospital STEMI care
Del Mar, California-based CeleCor Therapeutics has completed submission of a New Drug Application (NDA) to the US FDA for Disaggpro (zalunfiban), an...
Sangamo files for bankruptcy as Lilly and Astellas become stalking horse bidders for gene therapy assets
Richmond, California-based Sangamo Therapeutics, Inc. (OTCQB: SGMO) has entered into two separate asset sale agreements with Eli Lilly and Astellas Pharma,...
Duke University launches multiscale immune systems modeling center to link molecular dynamics with population-level disease outcomes
Duke University has received a USD 4.8 million NIAID U54 award to establish a Center for Multiscale Immune Systems Modeling, reflecting sustained federal...
Vellum Biotechnology develops electrophoresis-based method to unlock nucleic acids from archived tissue samples
Palo Alto-based Vellum Biotechnology, Inc. has received a USD 1.01 million NIH SBIR R44 grant from the National Human Genome Research Institute to develop...
The AllSci Brief
Free, systematic R&D and deal news. Daily.